Abstract
Crohn’s disease and ulcerative colitis are the major inflammatory bowel diseases (IBD) in humans. With the incidence of increasing world-wide, it currently affects 4 million people in Europe and in the USA. It is an idiopathic, chronic relapsing intestinal disorder of complex pathogenesis. The etiology of both diseases remains unknown, but recent data suggest that they appear in genetically predisposed individuals, because of an exaggerated mucosal immune response to commensal microbiota present in the gut. There is increasing evidence for an alteration of the immune regulation mechanisms in patients, with mucosal T lymphocytes playing a crucial role in the pathogenic events leading to tissue damage. It is clear that the disease is the result of environmental factors acting on genetically predisposed individuals. In humans, psychological trauma, stress or depression, have been involved as precipitating or relapsing factors of the disease, although this link remains elusive. However, several published works using colitis animal models subjected to stress conditions, have given consistent proof as to the molecular link between emotional stress, increase in epithelial permeability, alteration of the gut microflora composition and activation of pre-sensitized T lymphocytes. Gaining knowledge of the cross talk between components of the brain – gut – immune system axis may be fruitful in the design of future therapeutic approaches, such as the use of vasointestinal peptide (VIP) in this pathology.
Keywords: IBD (Inflammatory bowel disease), T lymphocytes, TLR, Stress, VIP, Gut-brain-immune system axis.
Current Pharmaceutical Design
Title:Neuroendocrine Stimulation of Mucosal Immune Cells in Inflammatory Bowel Disease
Volume: 20 Issue: 29
Author(s): Jose M. Martín-Villa
Affiliation:
Keywords: IBD (Inflammatory bowel disease), T lymphocytes, TLR, Stress, VIP, Gut-brain-immune system axis.
Abstract: Crohn’s disease and ulcerative colitis are the major inflammatory bowel diseases (IBD) in humans. With the incidence of increasing world-wide, it currently affects 4 million people in Europe and in the USA. It is an idiopathic, chronic relapsing intestinal disorder of complex pathogenesis. The etiology of both diseases remains unknown, but recent data suggest that they appear in genetically predisposed individuals, because of an exaggerated mucosal immune response to commensal microbiota present in the gut. There is increasing evidence for an alteration of the immune regulation mechanisms in patients, with mucosal T lymphocytes playing a crucial role in the pathogenic events leading to tissue damage. It is clear that the disease is the result of environmental factors acting on genetically predisposed individuals. In humans, psychological trauma, stress or depression, have been involved as precipitating or relapsing factors of the disease, although this link remains elusive. However, several published works using colitis animal models subjected to stress conditions, have given consistent proof as to the molecular link between emotional stress, increase in epithelial permeability, alteration of the gut microflora composition and activation of pre-sensitized T lymphocytes. Gaining knowledge of the cross talk between components of the brain – gut – immune system axis may be fruitful in the design of future therapeutic approaches, such as the use of vasointestinal peptide (VIP) in this pathology.
Export Options
About this article
Cite this article as:
Martín-Villa M. Jose, Neuroendocrine Stimulation of Mucosal Immune Cells in Inflammatory Bowel Disease, Current Pharmaceutical Design 2014; 20 (29) . https://dx.doi.org/10.2174/1381612820666140130205058
DOI https://dx.doi.org/10.2174/1381612820666140130205058 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Class II Phosphoinositide 3-Kinases as Potential Novel Drug Targets
Current Signal Transduction Therapy Cancer Invasion and Metastasis: Discovering New Targets For Diagnosis and Therapeutics
Current Signal Transduction Therapy Breast Cancer: Not Only a “Womans” Disease
Current Women`s Health Reviews Between Bench and Bed Side: PI3K Inhibitors
Current Molecular Pharmacology High Content, Multi-Parameter Analyses in Buccal Cells to Identify Alzheimer’s Disease
Current Alzheimer Research Herpes Simplex Virus-Induced Ocular Diseases: Detrimental Interaction Between Virus and Host
Current Immunology Reviews (Discontinued) Monoamine Receptors and Signal Transduction Mechanisms in Suicide
Current Psychiatry Reviews Recent Advances in Oncogenic Roles of the TRPM7 Chanzyme
Current Medicinal Chemistry Epigenetic Regulation of Epithelial to Mesenchymal Transition
Current Cancer Drug Targets A Recent Update on the Role of Ghrelin in Glucose Homeostasis
Current Diabetes Reviews Design of Bioartificial Pancreas with Functional Micro/Nano-Based Encapsulation of Islets
Current Pharmaceutical Biotechnology Integrins: Regulators of Tissue Function and Cancer Progression
Current Pharmaceutical Design Integrated, Molecular Engineering Approaches to Develop Prostate Cancer Gene Therapy
Current Gene Therapy Roles of SM22α in Cellular Plasticity and Vascular Diseases
Cardiovascular & Hematological Disorders-Drug Targets RNA Interference as a Therapeutic Strategy for the Treatment of Liver Diseases
Current Pharmaceutical Design Influence of Mutations in the Hepatitis B Virus Genome on Virus Replication and Drug Resistance - Implications for Novel Antiviral Strategies
Current Medicinal Chemistry Crosstalk Signalling Role in Modulation of Drugs Side Effects
Current Molecular Pharmacology Managing Expectations in the Transition to Proof of Concept Studies
Reviews on Recent Clinical Trials Growth Responses Following a Single Intra-Muscular hGH Plasmid Administration Compared to Daily Injections of hGH in Dwarf Mice
Current Gene Therapy Developing FGFR4 Inhibitors As Potential Anti-Cancer Agents Via In Silico Design, Supported by In Vitro and Cell-Based Testing
Current Medicinal Chemistry